PT - JOURNAL ARTICLE AU - N.A. Scott AU - S.B. Knight AU - L. Pearmain AU - O. Brand AU - D.J. Morgan AU - C. Jagger AU - S. Khan AU - P. Hackney AU - L. Smith AU - M. Menon AU - J. E. Konkel AU - H. A. Shuwa AU - M. Franklin AU - V. Kästele AU - S. Harbach AU - S. Brij AU - A. Ustianowski AU - A. Uriel AU - G. Lindergard AU - N. Diar Bakerly AU - P. Dark AU - A.G. Mathioudakis AU - K.J. Gray AU - G.M. Lord AU - T. Felton AU - C. Brightling AU - L-P Ho AU - NIHR Respiratory TRC AU - CIRCO AU - K. Piper Hanley AU - A. Simpson AU - J.R. Grainger AU - T. Hussell AU - E.R. Mann TI - Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 convalescence AID - 10.1101/2020.10.10.20207449 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.10.20207449 4099 - http://medrxiv.org/content/early/2020/10/16/2020.10.10.20207449.short 4100 - http://medrxiv.org/content/early/2020/10/16/2020.10.10.20207449.full AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in the clinical syndrome COVID-19 is associated with an exaggerated immune response and monocyte infiltrates in the lungs and other peripheral tissues. It is now increasingly recognised that chronic morbidity persists in some patients. We recently demonstrated profound alterations of monocytes in hospitalised COVID-19 patients. It is currently unclear whether these abnormalities resolve or progress following patient discharge. We show here that blood monocytes in convalescent patients at their 12 week follow up, have a greater propensity to produce pro-inflammatory cytokines TNFα and IL-6, which was consistently higher in patients with resolution of lung injury as indicated by a normal chest X-ray and no shortness of breath (a key symptom of lung injury). Furthermore, monocytes from convalescent patients also displayed enhanced levels of molecules involved in leucocyte migration, including chemokine receptor CXCR6, adhesion molecule CD31/PECAM and integrins VLA-4 and LFA-1. Expression of migration molecules on monocytes was also consistently higher in convalescent patients with a normal chest X-ray. These data suggest persistent changes in innate immune function following recovery from COVID-19 and indicate that immune modulating therapies targeting monocytes and leucocyte migration may be useful in recovering COVID-19 patients with persistent symptoms.Competing Interest StatementGL is Co-founder and Scientific Advisory Board Member of Gritstone Oncology Inc., which is a public company that develops therapeutic vaccines (primarily for the treatment of cancer). The other authors declare that they have no competing interests.Funding StatementThis work was supported by The Kennedy Trust for Rheumatology Research who provided a Rapid Response Award for costs associated with the laboratory analysis of the immune response in COVID-19 patients to JRG, The Wellcome Trust (TH, 202865/Z/16/Z; 106898/A/15/Z which helped support some CIRCO members), The Wellcome Trust/Royal Society (ERM, 206206/Z/17/Z), the Lister Institute (JEK) and BBSRC (JEK BB/M025977/1, TNS BB/S01103X/1), the Medical Research Council (LP MR/R00191X/1) and the NIHR Manchester Biomedical Research Centre (AGM). The Oxford, Leicester and Manchester NIHR BRC provided support for study design and sample collection.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Peripheral blood samples were collected at Manchester University Foundation Trust (MFT), Salford Royal NHS Foundation Trust (SRFT) and Pennine Acute NHS Trust (PAT) under the framework of the Manchester Allergy, Respiratory and Thoracic Surgery (ManARTS) Biobank (study no M2020-88) for MFT or the Northern Care Alliance Research Collection (NCARC) tissue biobank (study no. NCA-009) for SRFT and PAT. Ethical approval was given by North West Haydock Research Ethics Committee for ManARTS (REC ref: 20/NW/0302) and Wales Research Ethics Committee 4 for NCARC (REC ref: 18/WA/0368).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials.